Cargando…
G2/M inhibitors as pharmacotherapeutic opportunities for glioblastoma: the old, the new, and the future
Glioblastoma (GBM) is one of the deadliest tumors and has a median survival of 3 months if left untreated. Despite advances in rationally targeted pharmacological approaches, the clinical care of GBM remains palliative in intent. Since the majority of altered signaling cascades involved in cancer es...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Chinese Anti-Cancer Association
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372908/ https://www.ncbi.nlm.nih.gov/pubmed/30766748 http://dx.doi.org/10.20892/j.issn.2095-3941.2018.0030 |
_version_ | 1783394859171708928 |
---|---|
author | Castro-Gamero, Angel Mauricio Pezuk, Julia Alejandra Brassesco, María Sol Tone, Luiz Gonzaga |
author_facet | Castro-Gamero, Angel Mauricio Pezuk, Julia Alejandra Brassesco, María Sol Tone, Luiz Gonzaga |
author_sort | Castro-Gamero, Angel Mauricio |
collection | PubMed |
description | Glioblastoma (GBM) is one of the deadliest tumors and has a median survival of 3 months if left untreated. Despite advances in rationally targeted pharmacological approaches, the clinical care of GBM remains palliative in intent. Since the majority of altered signaling cascades involved in cancer establishment and progression eventually affect cell cycle progression, an alternative approach for cancer therapy is to develop innovative compounds that block the activity of crucial molecules needed by tumor cells to complete cell division. In this context, we review promising ongoing and future strategies for GBM therapeutics aimed towards G2/M inhibition such as anti-microtubule agents and targeted therapy against G2/M regulators like cyclin-dependent kinases, Aurora inhibitors, PLK1, BUB, 1, and BUBR1, and survivin. Moreover, we also include investigational agents in the preclinical and early clinical settings. Although several drugs were shown to be gliotoxic, most of them have not yet entered therapeutic trials. The use of either single exposure or a combination with novel compounds may lead to treatment alternatives for GBM patients in the near future. |
format | Online Article Text |
id | pubmed-6372908 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Chinese Anti-Cancer Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-63729082019-02-14 G2/M inhibitors as pharmacotherapeutic opportunities for glioblastoma: the old, the new, and the future Castro-Gamero, Angel Mauricio Pezuk, Julia Alejandra Brassesco, María Sol Tone, Luiz Gonzaga Cancer Biol Med Review Glioblastoma (GBM) is one of the deadliest tumors and has a median survival of 3 months if left untreated. Despite advances in rationally targeted pharmacological approaches, the clinical care of GBM remains palliative in intent. Since the majority of altered signaling cascades involved in cancer establishment and progression eventually affect cell cycle progression, an alternative approach for cancer therapy is to develop innovative compounds that block the activity of crucial molecules needed by tumor cells to complete cell division. In this context, we review promising ongoing and future strategies for GBM therapeutics aimed towards G2/M inhibition such as anti-microtubule agents and targeted therapy against G2/M regulators like cyclin-dependent kinases, Aurora inhibitors, PLK1, BUB, 1, and BUBR1, and survivin. Moreover, we also include investigational agents in the preclinical and early clinical settings. Although several drugs were shown to be gliotoxic, most of them have not yet entered therapeutic trials. The use of either single exposure or a combination with novel compounds may lead to treatment alternatives for GBM patients in the near future. Chinese Anti-Cancer Association 2018-11 /pmc/articles/PMC6372908/ /pubmed/30766748 http://dx.doi.org/10.20892/j.issn.2095-3941.2018.0030 Text en Copyright 2017 Cancer Biology & Medicine http://creativecommons.org/licenses/by-nc-sa/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ |
spellingShingle | Review Castro-Gamero, Angel Mauricio Pezuk, Julia Alejandra Brassesco, María Sol Tone, Luiz Gonzaga G2/M inhibitors as pharmacotherapeutic opportunities for glioblastoma: the old, the new, and the future |
title | G2/M inhibitors as pharmacotherapeutic opportunities for glioblastoma: the old, the new, and the future |
title_full | G2/M inhibitors as pharmacotherapeutic opportunities for glioblastoma: the old, the new, and the future |
title_fullStr | G2/M inhibitors as pharmacotherapeutic opportunities for glioblastoma: the old, the new, and the future |
title_full_unstemmed | G2/M inhibitors as pharmacotherapeutic opportunities for glioblastoma: the old, the new, and the future |
title_short | G2/M inhibitors as pharmacotherapeutic opportunities for glioblastoma: the old, the new, and the future |
title_sort | g2/m inhibitors as pharmacotherapeutic opportunities for glioblastoma: the old, the new, and the future |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372908/ https://www.ncbi.nlm.nih.gov/pubmed/30766748 http://dx.doi.org/10.20892/j.issn.2095-3941.2018.0030 |
work_keys_str_mv | AT castrogameroangelmauricio g2minhibitorsaspharmacotherapeuticopportunitiesforglioblastomatheoldthenewandthefuture AT pezukjuliaalejandra g2minhibitorsaspharmacotherapeuticopportunitiesforglioblastomatheoldthenewandthefuture AT brassescomariasol g2minhibitorsaspharmacotherapeuticopportunitiesforglioblastomatheoldthenewandthefuture AT toneluizgonzaga g2minhibitorsaspharmacotherapeuticopportunitiesforglioblastomatheoldthenewandthefuture |